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Use of JAK inhibitors in the management of myelofibrosis:
a revision of the British Committee for Standards in
Haematology Guidelines for Investigation and Management
of Myelofibrosis 2012
The British Committee for Standards in Haematology
(BCSH) Guidelines for myelofibrosis were produced in 2012
(Reilly et al, 2012), but since then Ruxolitinib, a JAK1/JAK2
inhibitor, has been approved for use in the European Union
and highly prevalent mutations in the Calreticulin gene
(CALR) have been described. We therefore wish to revise the
existing guideline (Reilly et al, 2012) to accommodate this
important data. Current diagnostic criteria should be modi-
fied to incorporate testing for the CALR mutations into
major criteria A2 alongside JAK2 V617F, as shown in Table I
(Evidence grade 1A). Patients with CALR mutations may have
a better prognosis (Klampfl et al, 2013), but this has not for-
mally been assessed and incorporated into prognostic scores.
Substantial data are now available concerning responses to
JAK inhibitor therapies including beneficial effects upon sur-
vival (Verstovsek et al, 2012, 2013; Cervantes et al, 2013).
For example, at 144 weeks in the COMFORT-II study the
median of overall survival had not been reached in either
arm. A total of 29 (199%) and 22 (301%) patients died
during the study in the ruxolitinib and best available therapy
(BAT) arms, respectively, of which deaths on treatment were
reported for 13 (89%) in the ruxolitinib arm, and 5 (68%)
in the BAT arm (one death occurred after crossover to ruxo-
litinib). There was a 52% reduction in risk of death in the
ruxolitinib treatment arm compared to the BAT arm (Haz-
ard Ratio = 048, 95% confidence interval 028–085). The
estimated probability of being alive at 144 weeks was 81% in
ruxolitinib arm and 61% in BAT arm. The P-value for the
log-rank test stratified by the baseline risk category was
0009, (Cervantes et al, 2013). Furthermore, data from these
randomized studies suggest that standard therapies are com-
parable to placebo in terms of spleen and symptom
responses. The previous guideline (Reilly et al, 2012) recom-
mended consideration of JAK inhibitor therapy for patients
who have failed hydroxycarbamide therapy and are not pres-
ently suitable for bone marrow transplantation, or for
patients with severe constitutional symptoms. In view of new
evidence we now formally recommend ruxolitinib as first line
therapy for symptomatic splenomegaly and/or myelofibrosis-
related constitutional symptoms regardless of JAK2 V617F
mutation status (evidence grade 1A) where the balance
between need to resolve the latter outweighs risk of side
effects and, in particular, we make the following recommen-
dations:
Indications:
1 Symptomatic splenomegaly. (evidence grade 1A)
2 Myelofibrosis-related symptoms that are impinging upon
quality of life. (evidence grade 1B)
3 Hepatomegaly and portal hypertension due to myelofibro-
sis are reduced by ruxolitinib (Verstovsek et al, 2010) and
it can be considered for these indications. (evidence grade
2B)
Whilst treatment with ruxolitinib is suggested to confer a
survival advantage treatment with this agent in asymptomatic
patients and/or those who lack bothersome splenomegaly is
not currently recommended.
Tolerance and side effects:
1 Anaemia and thrombocytopenia are to be anticipated with
this agent, anaemia usually peaking by weeks 12–16 and
improving thereafter. In patients with pre-existing anae-
mia and thrombocytopenia (NB, those patients with
Table I. Diagnostic criteria for primary myelofibrosis.
Diagnosis requires A1 + A2 and any two B criteria
A1 Bone marrow fibrosis ≥3 (on 0–4 scale)
A2 Pathogenetic mutation (e.g. in JAK2, CALR or MPL),
or absence of both BCR-ABL1 and reactive causes of
bone marrow fibrosis
B1 Palpable splenomegaly
B2 Unexplained anaemia
B3 Leuco-erthroblastosis
B4 Tear-drop red cells
B5 Constitutional symptoms*
B6 Histological evidence of extramedullary haematopoiesis
*Drenching night sweats, weight loss >10% over 6 months, unex-
plained fever (>375°C) or diffuse bone pains.
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platelet counts below 50 9 109/l are excluded from using
this drug) a lower starting dose is recommended for
example 5 mg BD (Harrison et al, 2013) (evidence grade
1B)
2 Anaemia may be ameliorated by lowering the dose of rux-
olitinib or by concomitant use of erythropoietin-stimulat-
ing agents, and/or anabolic steroids, such as danazol
(McMullin et al, 2011). (evidence grade 2B)
3 Given that there have been reports of reactivation of
latent and atypical infections, such as hepatitis B and
tuberculosis, the prescriber should actively screen for
these and use appropriate prophylactic measures. Live
vaccinations should be considered with caution. (evidence
grade 1B)
Monitoring response:
1 For objective monitoring of symptoms, a tool such as the
Myeloproliferative Neoplasm Symptom Assessment Form
(MPN-SAF)may be useful (Emanuel et al, 2012; Harrison
et al, 2013). (evidence grade 1A)
2 Recent response criteria for testing novel myelofibrosis
treatments have been suggested for use in clinical trials
(Tefferi et al, 2013), although these are not intended or
recommended for use in clinical practice.
3 The decision to stop ruxolitinib therapy will depend upon
a combination of different factors, including benefit upon
treatment target (usually spleen and/or symptoms) and
presence or absence of toxicity. The degree of target
spleen or symptom reduction has not yet been identified
and will be individual for each patient. It is recommended
that the dose should be modified to the maximum toler-
ated where response is not adequate and that treatment
should be continued for 24 weeks. A schematic for con-
sidering whether to continue or stop these agents is sug-
gested in Fig 1. (evidence grade 1B)
How to stop
1 Disease symptoms and splenomegaly will recur on drug
withdrawal, sometimes rapidly. A gradual dose tapering
over 7–10 d and avoidance of sudden interruptions are
recommended. Cover with systemic steroids (suggestion
20–30 mg of prednisolone) has also been used in these
circumstances (Harrison et al, 2013). (evidence grade 1A)
For patients failing or intolerant of ruxolitinib, additional
JAK inhibitors are being assessed in clinical trials and may be
approved in the future.
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